GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Algernon Pharmaceuticals Inc (XCNQ:AGN) » Definitions » Pre-Tax Income

Algernon Pharmaceuticals (XCNQ:AGN) Pre-Tax Income : C$-2.61 Mil (TTM As of May. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Algernon Pharmaceuticals Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Algernon Pharmaceuticals's pretax income for the three months ended in May. 2024 was C$1.44 Mil. Its pretax income for the trailing twelve months (TTM) ended in May. 2024 was C$-2.61 Mil. Algernon Pharmaceuticals's pretax margin was %.


Algernon Pharmaceuticals Pre-Tax Income Historical Data

The historical data trend for Algernon Pharmaceuticals's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Algernon Pharmaceuticals Pre-Tax Income Chart

Algernon Pharmaceuticals Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Pre-Tax Income
Get a 7-Day Free Trial Premium Member Only -1.90 -8.54 -7.73 -6.05 -6.78

Algernon Pharmaceuticals Quarterly Data
Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.13 -2.53 -0.52 -1.00 1.44

Competitive Comparison of Algernon Pharmaceuticals's Pre-Tax Income

For the Biotechnology subindustry, Algernon Pharmaceuticals's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Algernon Pharmaceuticals's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Algernon Pharmaceuticals's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Algernon Pharmaceuticals's Pre-Tax Income falls into.



Algernon Pharmaceuticals Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Algernon Pharmaceuticals's Pretax Income for the fiscal year that ended in Aug. 2023 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-5.242+-1.541+0+0.002+0
=-6.78

Algernon Pharmaceuticals's Pretax Income for the quarter that ended in May. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=1.198+0.245+0+0+0.00099999999999989
=1.44

Pre-Tax Income for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-2.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals  (XCNQ:AGN) Pre-Tax Income Explanation

Algernon Pharmaceuticals's Pretax Margin for the quarter that ended in May. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=1.444/0
=%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Algernon Pharmaceuticals Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Algernon Pharmaceuticals's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Algernon Pharmaceuticals Business Description

Traded in Other Exchanges
Address
601 West Broadway, Suite 400, Vancouver, BC, CAN, V5Z 4C2
Algernon Pharmaceuticals Inc is a clinical-stage drug development company focused on the disease areas of stroke, idiopathic pulmonary fibrosis and chronic cough. The company's business model is capital efficient and strives to deliver maximum shareholder value. Algernon's approach to drug discovery is based on the concept of drug repurposing. It operates in two reportable segments: the development of repurposed therapeutic drugs in Canada, and the facilitation of the Company's drug candidates into off-label phase II clinical trials (humans) in Australia.
Executives
Christopher Moreau Director, Senior Officer
Christopher Scott Bryan Senior Officer
James Kinley Senior Officer
Harry J.f. Bloomfield Director
Rajpaul Attariwala Director
Mark Williams Director
Howard Gutman Director
Michael Sadhra Senior Officer
Kulwant Malhi 10% Security Holder

Algernon Pharmaceuticals Headlines

No Headlines